Search hospitals > New York > New Hyde Park

Clinical Research Alliance

Claim this profile
New Hyde Park, New York 11042
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Lymphoma
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Chronic Lymphocytic Leukemia
68 reported clinical trials
3 medical researchers
Photo of Clinical Research Alliance in New Hyde ParkPhoto of Clinical Research Alliance in New Hyde ParkPhoto of Clinical Research Alliance in New Hyde Park

Summary

Clinical Research Alliance is a medical facility located in New Hyde Park, New York. This center is recognized for care of Lung Cancer, Breast Cancer, Lymphoma, Non-Small Cell Lung Cancer, Chronic Lymphocytic Leukemia and other specialties. Clinical Research Alliance is involved with conducting 68 clinical trials across 125 conditions. There are 3 research doctors associated with this hospital, such as James T D'Olimpio, MD, Morton MD Coleman, doctor, and James D Olimpio.

Area of expertise

1Lung Cancer
Global Leader
Clinical Research Alliance has run 24 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Clinical Research Alliance has run 23 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative

Top PIs

Clinical Trials running at Clinical Research Alliance

Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Cancer
Lymphoma
Pancreatic Cancer
Brain Tumor
MALT Lymphoma
Image of trial facility.

Cancer Vaccine

for Lung Cancer

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Acasunlimab + Pembrolizumab

for Lung Cancer

This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic setting.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Divarasib + Pembrolizumab

for Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Recruiting2 awards Phase 37 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Clinical Research Alliance?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security